patient subgroup...
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
antiviral and associated therapy - versus placebo - for COVID 19 hospitalized
method
abbreviations
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
00 death D28 0.94 [0.76, 1.16]< 1 22% 5 studies (5/-) 72.5 % low not evaluable high crucial - deaths 0.92 [0.77, 1.09]< 1 2% 17 studies (17/-) 84.2 % low low high crucial - deaths (time to event analysis only) 0.66 [0.46, 0.95]< 1 32% 2 studies (2/-) 98.7 % some concern not evaluable moderate crucial - clinical deterioration 1.00 [0.65, 1.53]< 1 0% 4 studies (4/-) 50.4 % some concern not evaluable moderate important - clinical improvement 1.14 [0.95, 1.37]> 1 39% 4 studies (4/-) 92.2 % some concern not evaluable moderate important - clinical improvement (14-day) 1.06 [0.79, 1.42]> 1 0% 2 studies (2/-) 64.6 % low not evaluable high important - clinical improvement (28-day) 1.21 [0.97, 1.51]> 1 17% 3 studies (3/-) 95.2 % some concern not evaluable moderate important - clinical improvement (7-day) 0.93 [0.81, 1.07]> 1 0% 4 studies (4/-) 15.5 % some concern not evaluable moderate important - clinical improvement (time to event analysis only) 1.18 [1.05, 1.32]> 1 10% 7 studies (7/-) 99.7 % some concern not evaluable moderate important - death or ventilation 1.01 [0.65, 1.57]< 1 0% 4 studies (4/-) 47.8 % some concern not evaluable moderate important - hospital discharge 1.02 [0.96, 1.08]> 1 0% 8 studies (8/-) 71.5 % NA not evaluable important - hospitalization 0.25 [0.08, 0.83]< 1 0% 2 studies (2/-) 98.8 % NA not evaluable important - mechanical ventilation 1.36 [0.67, 2.79]< 1 0% 3 studies (3/-) 19.7 % some concern not evaluable moderate important - viral clearance 0.91 [0.77, 1.06]> 1 0% 3 studies (3/-) 11.1 % low not evaluable high important - viral clearance (time to event analysis only) 1.58 [0.31, 8.10]> 1 83% 2 studies (2/-) 70.6 % low not evaluable high important - viral clearance by day 14 4.10 [1.12, 14.99]> 1 0% 1 study (1/-) 98.3 % NA not evaluable important - viral clearance by day 7 0.92 [0.78, 1.08]> 1 0% 3 studies (3/-) 15.4 % low not evaluable high important - ICU admission 1.12 [0.47, 2.64]< 1 0% 3 studies (3/-) 40.1 % some concern not evaluable moderate non important - off oxygenation 0.98 [0.64, 1.51]> 1 0% 1 study (1/-) 46.4 % NA not evaluable non important - recovery 0.97 [0.89, 1.05]> 1 0% 1 study (1/-) 23.5 % NA not evaluable non important - 00 AE leading to drug discontinuation 2.43 [0.79, 7.45]< 1 0% 1 study (1/-) 6.0 % NA not evaluable important - serious adverse events 0.75 [0.59, 0.96]< 1 0% 5 studies (5/-) 98.8 % some concern not evaluable moderate important - adverse events 2.14 [0.93, 4.91]< 1 83% 6 studies (6/-) 3.7 % low not evaluable high non important - deep vein thrombosis 0.62 [0.23, 1.64]< 1 0% 2 studies (2/-) 83.1 % some concern not evaluable moderate non important - elevated liver enzymes 0.58 [0.34, 0.97]< 1 6% 2 studies (2/-) 98.1 % some concern not evaluable moderate non important - hyperbilirubinemia 0.97 [0.48, 1.93]< 1 0% 2 studies (2/-) 53.8 % low not evaluable high non important - pulmonary embolism 0.82 [0.20, 3.29]< 1 0% 2 studies (2/-) 61.1 % some concern not evaluable moderate non important - renal impairment 1.02 [0.64, 1.61]< 1 0% 2 studies (2/-) 47.2 % some concern not evaluable moderate non important - severe adverse events 1.21 [0.02, 64.67]< 1 0% 1 study (1/-) 46.4 % NA not evaluable non important -
LoD: level of statistical demonstration:
